Topical ruxolitinib for treating lichen planus
AssigneesIncyte Corporation, Mayo Foundation for Medical Education and Research
InventorsAaron R. MANGOLD, Ahmad B. NAIM
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to topical treatment of lichen planus (LP) using ruxolitinib, or a pharmaceutically acceptable salt thereof.
Claims78
A method of treating cutaneous lichen planus in a human patient in need thereof, comprising administering to an affected area of said human patient, a topical formulation two times per day, wherein said topical formulation comprises 1.5% (w/w) on a free base basis of ruxolitinib, or a pharmaceutically acceptable salt thereof.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.